相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。atpD gene sequencing, multidrug resistance traits, virulence-determinants, and antimicrobial resistance genes of emerging XDR and MDR-Proteus mirabilis
Abdelazeem M. Algammal et al.
SCIENTIFIC REPORTS (2021)
Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria mellonella survival model analysis
Jovan Borjan et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
In vitro selection of aztreonam/avibactam resistance in dual-carbapenemase-producing Klebsiella pneumoniae
Siqiang Niu et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Resistance to ceftazidime-avibactam and underlying mechanisms
Yuhang Wang et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)
Prevalence, the antibiogram and the frequency of virulence genes of the most predominant bacterial pathogens incriminated in calf pneumonia
Abdelazeem M. Algammal et al.
AMB EXPRESS (2020)
Emerging MDR-Pseudomonas aeruginosa in fish commonly harbor oprL and toxA virulence genes and blaTEM, blaCTX-M, and tetA antibiotic-resistance genes
Abdelazeem M. Algammal et al.
SCIENTIFIC REPORTS (2020)
Colistin Update on Its Mechanism of Action and Resistance, Present and Future Challenges
Ferdinando F. Andrade et al.
MICROORGANISMS (2020)
Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa
Sandra Mikhail et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo
Stephan Goettig et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing Klebsiella pneumoniae
Dominika Ojdana et al.
MICROBIAL DRUG RESISTANCE (2019)
Resistance reported from China antimicrobial surveillance network (CHINET) in 2018
Fupin Hu et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2019)
In vitro activities of ceftazidime/avibactam alone or in combination with antibiotics against multidrug-resistant Acinetobacter baumannii isolates
Emel Mataraci Kara et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2019)
Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections
Matt Shirley
DRUGS (2018)
In vitro activity of minocycline combined with aminoglycosides against Klebsiella pneumoniae carbapenemase-producing K-pneumoniae
Ni Wentao et al.
JOURNAL OF ANTIBIOTICS (2018)
Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study
Ai-jun Pan et al.
JOURNAL OF ANTIBIOTICS (2017)
Carbapenem Resistance, Initial Antibiotic Therapy, and Mortality in Klebsiella pneumoniae Bacteremia: A Systematic Review and Meta-Analysis
Philipp P. Kohler et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2017)
Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity
Kirk Nelson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam
Jean-Marie Pages et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections
Ryan K. Shields et al.
CLINICAL INFECTIOUS DISEASES (2016)
Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections
Jose A. Hidalgo et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
In Vitro Selection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase
David M. Livermore et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution
Tobias Bollenbach
CURRENT OPINION IN MICROBIOLOGY (2015)
Bactericidal Activity, Absence of Serum Effect, and Time-Kill Kinetics of Ceftazidime-Avibactam against β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa
Tiffany R. Keepers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Bacterial evolution of antibiotic hypersensitivity
Viktoria Lazar et al.
MOLECULAR SYSTEMS BIOLOGY (2013)
Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor
David E. Ehmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Synergy among antibacterial peptides and between peptides and small-molecule antibiotics
Marco Cassone et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2010)
In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor
A Bonnefoy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Plasmid-mediated, carbapenem-hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates
ES Moland et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Restricting the selection of antibiotic-resistant mutant bacteria: Measurement and potential use of the mutant selection window
XL Zhao et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
分享论文
